BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

Afcons Infrastructure Share Price, IPO Listing 2024 Highlights: Afcons Infrastructure's grey market premium (GMP) indicated a modest listing discount of Rs 3 to the issue price. (Image ...

A lot of action in the Indian IPO market has been lined up for Wednesday, with a couple of companies announcing their price bands and more. Two IPO-bound companies- Swiggy and Sagility- have ...

Afcons Infrastructure Share Price, IPO Listing 2024 Highlights: Afcons Infrastructure's grey market premium (GMP) indicated a modest listing discount of Rs 3 to the issue price. (Image ...

The Initial Public Offering (IPO) of Hyundai Motor India Limited, the Indian arm of South Korean automaker Hyundai, got fully subscribed on the third day of the bidding on Thursday (October 17, ...

How to financially benefit when Lulu sells 25 per cent stake to new investors The much-awaited initial public offering (IPO) of one of the Middle East's largest hypermarket chains opened for ...

Sharp weakness in the equity market seems to have dampened the primary market mood for the near term as there will be no new IPO launch in the coming (Diwali) week starting from October 28.

Septerna now offering 16 mln shares vs 15.3 mln shares earlier Sets IPO price at $18 a share Drug developer backed by Goldman, Third Rock Ventures Listing follows a spate of biotech IPOs since ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...